Telix Pharmaceuticals Limited TLX
11.45
0.14
1.24%
as of 25 Sep
- Market cap
- $3.9B
- P/E
- —
Follow TLX
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Dec '25 | Jun '25 | Dec '24 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
2.01 | 1.43 | 1.33 | 2.78 |
+2 more quarters Free account |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
42.29% | 39.65% | 34.45% | 38.25% | |
Debt/Equity |
1.18 | 1.11 | 0.97 | 1.02 | |
Asset Turnover |
0.00 | 0.00 | — | — | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | (1.20) | 0.00 | (1.79) | |
Intangible Assets out of Total Assets |
0.43 | 0.51 | 0.49 | 0.29 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
8.25 | (42.98) | (6.03) | 18.94 | |
Working Capital |
245.68 | 98.66 | 99.43 | 365.03 | |
Capital Expenditures |
(14.79) | (25.69) | (23.78) | (9.45) | |
Net Current Asset Value |
(386.15) | (418.33) | (370.00) | (17.32) | |
| Other line items | |||||
Quick Ratio |
1.71 | 1.17 | 1.11 | 2.57 | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Receivables |
111.24 | 86.12 | — | — | |
Average Payables |
112.28 | 102.32 | — | — | |
Average Inventory |
29.67 | 24.29 | — | — | |
Average Assets |
926.94 | 716.85 | — | — | |
Average Common Equity |
377.07 | 257.16 | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates